Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases.
Mediocre balance sheet with limited growth.
Share Price & News
How has Retrophin's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RTRX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RTRX underperformed the US Biotechs industry which returned 26.7% over the past year.
Return vs Market: RTRX underperformed the US Market which returned 7.4% over the past year.
Price Volatility Vs. Market
How volatile is Retrophin's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StDid Changing Sentiment Drive Retrophin's (NASDAQ:RTRX) Share Price Down By 49%?
2 months ago | Simply Wall StShould You Be Concerned About Retrophin, Inc.'s (NASDAQ:RTRX) Historical Volatility?
2 months ago | Simply Wall StHealth Check: How Prudently Does Retrophin (NASDAQ:RTRX) Use Debt?
Is Retrophin undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: RTRX ($20.89) is trading above our estimate of fair value ($7.29)
Significantly Below Fair Value: RTRX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RTRX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: RTRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RTRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RTRX is overvalued based on its PB Ratio (4x) compared to the US Biotechs industry average (3.5x).
How is Retrophin forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RTRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RTRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RTRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RTRX's revenue (23.5% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: RTRX's revenue (23.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RTRX's Return on Equity is forecast to be high in 3 years time
How has Retrophin performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RTRX is currently unprofitable.
Growing Profit Margin: RTRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RTRX is unprofitable, and losses have increased over the past 5 years at a rate of -50.9% per year.
Accelerating Growth: Unable to compare RTRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RTRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: RTRX has a negative Return on Equity (-46.35%), as it is currently unprofitable.
How is Retrophin's financial position?
Financial Position Analysis
Short Term Liabilities: RTRX's short term assets ($406.6M) exceed its short term liabilities ($68.1M).
Long Term Liabilities: RTRX's short term assets ($406.6M) exceed its long term liabilities ($279.2M).
Debt to Equity History and Analysis
Debt Level: RTRX's debt to equity ratio (88.6%) is considered high.
Reducing Debt: RTRX's debt to equity ratio has increased from 50.1% to 88.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RTRX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RTRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Retrophin current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RTRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RTRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RTRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RTRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RTRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Eric Dube (47yo)
Dr. Eric M. Dube Ph.D. is Head of North America of ViiV Healthcare Limited. Dr. Dube serves as President and Chief Executive Officer at Retrophin, Inc since January 4, 2019 and its Director since January 2 ...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD9.68M) is above average for companies of similar size in the US market ($USD3.13M).
Compensation vs Earnings: Insufficient data to compare Eric's compensation with company performance.
|CFO & Senior VP||5.67yrs||US$1.30m||0.039% $406.8k|
|Senior VP and Head of Research & Development||3.5yrs||US$1.31m||0.047% $490.7k|
|Chief Medical Officer||2yrs||US$1.37m||0.054% $558.4k|
|Chief Commercial Officer||0.75yr||US$1.33m||no data|
|Vice President of Investor Relations & Corporate Communications||no data||no data||no data|
|Senior VP||3.5yrs||US$1.59m||0.051% $531.2k|
|Vice President of Corporate Development||2.33yrs||no data||no data|
Experienced Management: RTRX's management team is considered experienced (2.3 years average tenure).
|Independent Director||3.33yrs||US$243.15k||0.024% $248.0k|
|Independent Chairman of the Board||4.17yrs||US$265.65k||0.068% $710.2k|
|Member of Scientific Advisory Board||no data||no data||no data|
|Independent Director||4.08yrs||US$243.15k||0.028% $292.4k|
|Independent Director||5.33yrs||US$255.65k||0.064% $668.4k|
|Independent Director||3.25yrs||US$238.15k||0.024% $248.0k|
|Independent Director||5.75yrs||US$250.15k||0.13% $1.3m|
|Member of Scientific Advisory Board||no data||no data||no data|
Experienced Board: RTRX's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RTRX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.8%.
Retrophin, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Retrophin, Inc.
- Ticker: RTRX
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.037b
- Shares outstanding: 49.66m
- Website: https://www.retrophin.com
Number of Employees
- Retrophin, Inc.
- 3721 Valley Centre Drive
- Suite 200
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RTRX||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Dec 2012|
|17R||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2012|
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company’s product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/07 23:58|
|End of Day Share Price||2020/07/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.